XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Other Assets | 12 Months Ended
--- | ---
Dec. 31, 2024
Other Assets [Abstract] |
Other assets | 12. Other assets
| Year ended December 31, |
| 2024 |  | 2023 |
| $000s |  | $000s |
Prepayments |  | 13,124 |  |  | 10,385 |
VAT receivable |  | 1,540 |  |  | 1,245 |
Total other current assets |  | 14,664 |  |  | 11,630 |
Deposits for properties |  | 356 |  |  | 362 |
Prepayments |  | 3,234 |  |  | 3,284 |
Other long-term assets |  | 3,590 |  |  | 3,646 |
At December 31, 2024 and 2023, the largest component of prepayments are prepaid third party costs for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies which fluctuate based on timing of payments and related expense. Included within prepayments at December 31, 2024 and 2023 is $11.0 million and $8.7 million respectively, are expenditures relating to research and development.

X
- References No definition available. + Details
Name: | us-gaap_OtherAssetsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets. + References No definition available. + Details
Name: | us-gaap_OtherAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration